Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment

Qlucore, a leader in software development for precision cancer diagnostics, has passed the evaluation phase and will receive a prestigious EIC Accelerator grant of 2,5 million Euros to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. In March the grant was made public and Qlucore is now starting the project and has received the first payment.

During the project Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for the two cancer types. The project will stretch over three years, with objectives to develop solutions for use by clinical laboratories as well as companion diagnostics (CDx) solutions in collaboration with pharma companies.
 
The selected cancer disease areas are especially suited to the solutions as both cancer types have multiple changes on RNA level that can be utilized to improve diagnosis and treatment. Currently this information is not fully used to provide the right therapy for the right patient. The aim of the project is to change this.
 
“The recognition from the expert review panels of our solutions and the addressed clinical need is a great endorsement of our strategic direction and focus on RNA-based solutions. RNA-based solutions are gaining momentum, allowing for cancer classification using gene fusions and gene expression signatures”, says Carl-Johan Ivarsson, CEO of Qlucore
 
For a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. For this project Qlucore will build on the significant investments in its solutions for acute lymphoblastic leukemia, Qlucore Diagnostics BCP-ALL, both from a software technical point of view and from a quality management system (QMS) point of view
 
"Receiving this grant in the company of tough competition further endorses our position at the forefront of RNA-seq based modern clinical diagnostics. This award will strengthen Qlucore financially as well as in the market", says Carl-Johan Ivarsson, CEO of Qlucore.
 
Intended customers are clinical laboratories in Europe in the first phase and the US market in a second phase. Qlucore is looking to use the solution in parallel for companion diagnostics (CDx) together with pharma companies.

FNCA Sweden AB
Web: www.fnca.se

Press contact:
Michael Bull/Mandy Brooks
Brookscomm
Phone: +44 (0) 1483 537 890
Email: michael@brookscomm.com mandy@brookscomm.com 

Qlucore contact:
Carl-Johan Ivarsson, CEO
Phone: +46 (0) 46 286 31 14
Email: carl-johan.ivarsson@qlucore.com 
(Photograph of Carl-Johan bellow) 

Ends

Qlucore is a leading provider of new generation intuitive bioinformatics software for research and precision and companion diagnostics. Qlucore’s mission is to make it easier to analyze the huge amounts of complex data generated by innovations in the fields of genomics and proteomics by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics. Qlucore Omics Explorer software is a easy to use bioinformatics software for research in the life science, plant- and biotech industries, as well as in academia. Qlucore Diagnostics and Qlucore Insights are software platforms with built in AI-based machine learning for multi-omics companion and precision diagnostics. Qlucore was founded in 2007 in Lund, Sweden and has customers in about 25 countries around the world, with sales offices in Europe and North America, and distribution in several countries in Asia. Qlucore is listed on the Nasdaq First North Growth market. www.qlucore.com